News und Analysen
![Dexcom Reports First Quarter 2020 Financial Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom Reports First Quarter 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020.
First Quarter 2020 and COVID-19 Pandemic Response Highlights:
-
Revenue grew 44%
![Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation
![Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation
![Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation
![PFIZER REPORTS FIRST-QUARTER 2020 RESULTS](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and updated certain other components of
![PFIZER REPORTS FIRST-QUARTER 2020 RESULTS](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and updated certain other components of
![LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen für Medizintechnik und Innovationen, gab heute bekannt, dass seine Bi-Flow-Kanüle für extrakorporale Membranoxygenierung (ECMO) die
![EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for
![Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) systems for people with diabetes, announced today a new patient assistance program to aid current U.S. customers who
![Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) systems for people with diabetes, announced today a new patient assistance program to aid current U.S. customers who
![Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I
Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a
![Aurinia Appoints Joe Miller as Chief Financial Officer](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Aurinia Appoints Joe Miller as Chief Financial Officer
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) ("EOS"), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical
![Premier Inc. to Report Fiscal 2020 Third-Quarter Results and Host Conference Call Before Market Opens on May 5](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Premier Inc. to Report Fiscal 2020 Third-Quarter Results and Host Conference Call Before Market Opens on May 5
Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 third-quarter financial results the morning of May 5, 2020, followed by a conference call at 8 a.m. ET to discuss the results.
Conference
![GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
![GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
![Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 7, 2020, following the release of its first quarter
![Pfizer Hosts Virtual-Only Annual Meeting of Shareholders](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
![Pfizer Hosts Virtual-Only Annual Meeting of Shareholders](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
![Humana and the National Quality Forum Publish Population Health Paper in the New England Journal of Medicine](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Humana and the National Quality Forum Publish Population Health Paper in the New England Journal of Medicine
Physician leaders from Humana Inc. (NYSE: HUM) and the National Quality Forum (NQF) explore the impact that social, behavioral and environmental factors – such as access to healthy foods, safe
![Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients
![Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
![Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
![Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und